Now GSK Will Make Influenza Covid Vaccines
In a strategic move that underscores the growing importance of mRNA technology in vaccine development, GSK has acquired full rights from CureVac to develop and manufacture mRNA-based vaccine candidates for Influenza and COVID-19. This significant deal, valued at up to 1.05 billion euros ($1.13 billion), marks a pivotal moment in GSK’s efforts to expand its…